India's Ranbaxy gets final U.S. nod for migraine drug
MUMBAI |
MUMBAI Aug 11 (Reuters) - Indian drugmaker Ranbaxy Laboratories (RANB.BO) said on Tuesday that it had got final approval from the U.S. Food and Drug Administration to make and sell sumatriptan succinate tablets, used to treat migraine. (Reporting by Janaki Krishnan; Editing by Himani Sarkar)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters